Chloromethyl isopropyl carbonate, model code CMIC-PG (CAS 35180-01-9, molecular formula C₅H₉ClO₃, relative molecular mass 152.58 g/mol), is a pharmaceutical-grade synthetic intermediate used for the preparation of carbonate promoiety-containing active pharmaceutical ingredients. It is a clear, colorless to pale yellow liquid with a supplier-reported density of 1.15 g/mL at 25 °C. The material is released under ICH Q7 as a GMP starting material, but it is not a finished API and does not enter tablet, capsule, granule, or injection formulations directly. Its principal industrial application is the alkylation of phosphonate and carboxylate substrates, most notably the synthesis of tenofovir disoproxil fumarate; the derived API is subsequently formulated into oral solid dosage forms or parenteral products.

The distinction between pharmaceutical grade and technical grade material is meaningful in production. Technical grade CMIC may be offered at 95% assay with uncontrolled moisture, residual solvent, and bioburden profiles, while CMIC-PG is packaged under nitrogen and released with a defined impurity and moisture profile. This difference reduces the downstream purification burden for APIs that must meet ICH Q3A(R2) and ICH Q3C(R8) limits. For injectable-grade synthesis, additional release data for endotoxin and bioburden are supplied.

CMIC is a lachrymatory, moisture-sensitive alkylating agent. It should be handled in a closed system with local exhaust ventilation. Aqueous waste containing the reagent is quenched with dilute sodium hydroxide in a cooled, vented vessel before discharge; the neutralization hydrolyzes the carbonate and generates isopropanol and chloride. The product is incompatible with water, alcohols, primary and secondary amines, strong bases, and nucleophilic solvents. Carbon steel is not acceptable in the presence of moisture because hydrochloric acid released during hydrolysis corrodes the metal; stainless steel grade 316L may be used for dry transfer, while glass-lined or fluoropolymer-lined equipment is required for wet or reactive service.

Why Is Anhydrous Handling a Critical Control Point in CMIC-Mediated Alkylation?

Water reacts with the chloromethyl carbonate functionality, releasing acidic hydrolytic by-products and consuming the reagent. At moisture contents above the release limit of 0.05% w/w, storage stability decreases and GC purity drift is observed. In process development campaigns, drum pumps left open to ambient air for more than 30 minutes during decanting produced moisture excursions of 0.04% to 0.08% w/w; subsequent assay values were lower by 0.3% area and additional unspecified impurities were detected. Consequently, dedicated PTFE-lined pump kits with silica-gel drying tubes are specified for all scale-up transfers.

Large-scale alkylation is performed in glass-lined reactors of 500 L to 2,000 L. The reactor is dried by vacuum stripping or toluene distillation before addition, and CMIC is charged through a PTFE-lined dip tube under a nitrogen atmosphere. In public supplier technical bulletins for tenofovir disoproxil fumarate processes, the substrate is dissolved in an anhydrous polar aprotic solvent such as N-methyl-2-pyrrolidone, a tertiary amine acid scavenger is added, and CMIC is metered into the batch to maintain an internal temperature of 30 °C to 50 °C. The reaction is monitored by high-performance liquid chromatography for disappearance of the starting phosphonate and formation of the disoproxil intermediate. CMIC is applied at 2.2 to 2.5 molar equivalents relative to tenofovir; lower ratios leave monoalkylated phosphonate, while higher ratios increase carbonate-derived process impurities that affect crystallization of the fumarate salt.

The chloromethyl carbonate feed line is dedicated and kept free of alcohols, water, and primary or secondary amines. Tertiary amines such as triethylamine are used as hydrogen chloride scavengers; primary and secondary amines can consume CMIC through carbamate formation and are not introduced into the feed vessel. Reactor vents are routed to an aqueous alkali scrubber because the decomposition products include acidic volatile species. Storage is in fluoropolymer-lined containers under nitrogen at 2 °C to 8 °C; a retest period of 12 months is typical when the container remains sealed.

Chloromethyl isopropyl carbonate differs from chloromethyl methyl carbonate and chloromethyl ethyl carbonate primarily by the steric demand of the isopropyl substituent at the carbonate carbonyl. The methyl and ethyl homologs are less hindered and may be selected when faster esterase-mediated hydrolysis or lower lipophilicity is required in the derived prodrug. CMIC provides a secondary alkyl group that moderates carboxylesterase interactions and increases lipophilicity relative to the methyl homolog. Direct comparative hydrolysis rate constants under identical in vitro conditions are not comprehensively published, so the selection of CMIC for tenofovir disoproxil fumarate is supported by product-specific development data rather than isolated kinetic ranking. The oral bioavailability of tenofovir disoproxil fumarate under fasting conditions is approximately 25% according to approved labeling; this value is a property of the complete prodrug and final API, not of CMIC alone. Chloromethyl pivalate, used in adefovir dipivoxil synthesis, carries a bulkier pivaloyl moiety and is not interchangeable with CMIC in an approved tenofovir disoproxil fumarate route without altering impurity profiles and dissolution performance of the derived API.

When the Intended Downstream API Must Meet an Injectable Endotoxin Budget

For APIs destined for injectable dosage forms, CMIC should be released with bacterial endotoxin and bioburden data because the final purification may not reduce endotoxin below an acceptable limit after crystallization. A supplier release limit of ≤0.10 EU/mg is commonly requested for the reagent, though the final acceptance criterion is derived from the maximum endotoxin limit of the injectable product and the maximum daily dose. The downstream API is generally sterile-filtered through a 0.22 µm membrane and may be lyophilized. Closed transfer of CMIC under nitrogen reduces bioburden ingress; open handling of the non-sterile chemical in an uncontrolled environment is not considered suitable for injectable synthesis. This control is part of the raw material risk assessment required under ICH Q9 and the finished drug sterility assurance program.

Specification Profile and Compendial Alignment for Release of CMIC-PG

No pharmacopoeial monograph exists for chloromethyl isopropyl carbonate as a raw material, so release methods are validated according to ICH Q2(R1). Gas chromatographic assay is performed with flame ionization detection and a capillary column of 30 m × 0.25 mm internal diameter with a 0.25 µm 5% phenyl methylpolysiloxane stationary phase. The injector and detector temperatures are set at 250 °C and 300 °C, respectively, with a split ratio of 20:1. The method is capable of detecting individual impurities at 0.02% area or below. The representative release criteria below are compiled from supplier certificates of analysis for pharma grade shipments. Actual site-specific limits may vary according to the intended downstream API process.

Residual solvent limits are applied according to ICH Q3C(R8) Table 2 for Class 2 and Class 3 solvents. Elemental impurity limits are based on ICH Q3D Option 1 and the anticipated daily dose of the derived API. Since CMIC is not present in the final tablet, capsule, granule, or injection, specification tests such as dissolution, tablet hardness, capsule fill weight, content uniformity, and injection particulate matter are not part of the reagent release profile; they are controlled on the derived API and the finished dosage form.

In oral solid dosage manufacture, the API prepared from CMIC is processed by direct compression, dry granulation, or wet granulation. A wet granulation process for tenofovir disoproxil fumarate tablets may use lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium as primary excipients, with a final granule loss on drying of ≤2.0% w/w. The granule is milled, blended with a lubricant such as magnesium stearate, and compressed into tablet cores; hardness and disintegration are measured per USP 〈1217〉 and USP 〈701〉, respectively. For capsule dosage forms, the same granulate or powder blend may be filled into hard gelatin or HPMC capsules, with fill weight determined by the API assay and content uniformity tested per USP 〈905〉. None of these unit operations involve direct addition of CMIC.

If Carbonate-Derived Process Impurities Must Fall Below ICH Q3A Reporting Thresholds

In the derived API, chloromethyl isopropyl carbonate-related impurities such as mono-substituted intermediates, isopropanol, and chloride are controlled through reaction stoichiometry, aqueous work-up, and crystallization. For tenofovir disoproxil fumarate, individual process impurities are typically limited to ≤0.10% or lower, with total impurities ≤0.50%. The final API specification is designed to meet ICH Q3A(R2) reporting, identification, and qualification thresholds. Residual CMIC is not usually monitored directly in the final dosage form because it hydrolyzes in aqueous media; instead, the corresponding residual solvents and degradation products are measured. Process validation batches establish the correlation between the CMIC molar ratio and unreacted carbonate-related impurities in the isolated API. Published data for this specific configuration is limited, so site-specific validation data are required.